StreetAlpha.app
Home › Stocks › ASMB

Assembly Biosciences, Inc. (ASMB)

$22.50
▲ +5.68%
LAST CLOSE · NOV 17

Assembly Biosciences develops antiviral medicines for serious viral diseases, including genital herpes and hepatitis. It last closed at $22.50 on Nov 17, up 5.68% on the day.

AI Auto Pilots
Is ASMB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$67.0M
+80.2% vs a year ago
Net income
−$11.1M
−16.6% margin
Free cash flow
−$40.7M
−60.7% margin
Operating margin
−31.8%
−$21.3M operating income
Valuation
Market cap
$460.7M
20.5M shares
P/E
–
Price to sales
6.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.1M
At Sep 30
Shareholder equity
$298.8M
Shares outstanding
20.5M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $6.3M$6.3MFY2021FY2022: $0$0FY2022FY2023: $7.2M$7.2MFY2023FY2024: $28.5M$28.5MFY2024FY2025: $72.3M$72.3MFY2025

From ASMB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ASMB in the past 90 days, not enough for a consensus
Average 12-month target
$48.00
▲ 113.3% upside

Based on 1 analyst who set a price target on ASMB in the past 90 days. The average target is $48.00, with a high of $48.00 and a low of $48.00, compared with the last close of $22.50.

Low $48.00Avg $48.00High $48.00
Blue marker: last close $22.50
Highest target$48.00
Average target$48.00
Lowest target$48.00
Latest rating changes
UBSTarget lowered
Nov 3Buy$52 → $48
UBSInitiated
Sep 1Buy$52
HC Wainwright & Co.Reiterated
Aug 18Buy$50
MizuhoMaintained
Jun 15Buy$45
DateFirmActionRatingPrice target
Nov 3UBSTarget loweredBuy$52 → $48
Sep 1UBSInitiatedBuy$52
Aug 18HC Wainwright & Co.ReiteratedBuy$50
Jun 15MizuhoMaintainedBuy$45
Loading…

Technical Analysis

ASMB · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock sits between its 20 and 50 day averages. It is 19% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 56). The nearest support is the Pivot at $22.12, and the nearest resistance the swing high (Nov 11) at $22.69.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityNormal, 5.6%/day
Key levels
$39.7152 week high+76.5%
$26.81200 day average+19.2%
$26.02100 day average+15.6%
$22.98Pivot R1+2.1%
$22.6950 day average+0.8%
$22.69Swing high (Nov 11)+0.8%
$22.50Last close
$22.12Pivot−1.7%
$21.80Swing low (Jun 11)−3.1%
$21.64Pivot S1−3.8%
$20.6220 day average−8.4%
$19.2052 week low−14.7%
Indicators
RSI (14)55.53Middle of its rangeNeutral
MACD-0.28Above its signal lineBullish
Stochastic69.8Middle of its rangeNeutral
ADX (14)23.0Weak trend
Williams %R-5.4Oversold below −80, overbought above −20Overbought
CCI (20)176.2Oversold below −100, overbought above 100Overbought
Rate of change+12.9%Change over 10 sessionsBullish
ATR (14)$1.27Typical daily range, 5.6% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for ASMB

What happened before

See how ASMB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ASMB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ASMB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ASMB in the last 90 days.

Loading…

See today’s whale options flow across the market →

ASMB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲71 buying vs 29 selling
  • ▲Held by funds +2.1 pts
  • ▲Funds holding +10
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10494+10.6%
In funds' top 1013−66.7%
Held by funds93.7%91.6%+2.1 pts
New / increased22 / 4932 / 35+6.0%
Reduced / sold out16 / 1317 / 15−9.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ASMB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ASMB is in one of them and how their past ASMB trades turned out.

ASMB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ASMB in an article yet. Here's the latest on the wider market.

ASMB Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Feb 17
Who traded ASMB · since 2020
Latest 2 filings
$1K – $15KTraded Jan 4, 2021Filed Feb 17, 2021
$1K – $15KTraded Dec 28, 2020Filed Feb 10, 2021
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYSell$1K – $15KJan 4, 2021Feb 17, 202144 d
Christopher JacobsR · NYBuy$1K – $15KDec 28, 2020Feb 10, 202144 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Assembly Biosciences

Assembly Biosciences is a biotechnology company based in South San Francisco, California, that develops antiviral medicines for people with serious viral diseases. Its experimental treatments target genital herpes, hepatitis delta, hepatitis B and herpesviruses that can affect transplant patients. Gilead Sciences has licensed its genital herpes program, and the company is seeking partners for its hepatitis B candidate. Its other programs remain in clinical testing or early research.

Headquarters
South San Francisco, CA